Vivendy Therapeutics
Basel
About Vivendy Therapeutics
Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $45.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2008)
- Website: vivendy.ch
- Phone: +41 61-271-8780
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/vivendy-therapeutics-975555 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.